Abstract:BackgroundHeparosan is the unsulfated precursor of heparin and heparan sulfate and its synthesis is typically the first step in the production of bioengineered heparin. In addition to its utility as the starting material for this important anticoagulant and anti-inflammatory drug, heparosan is a versatile compound that possesses suitable chemical and physical properties for making a variety of high-quality tissue engineering biomaterials, gels and scaffolds, as well as serving as a drug delivery vehicle. The selected production host was the Gram-positive bacterium Bacillus megaterium, which represents an increasingly used choice for high-yield production of intra- and extracellular biomolecules for scientific and industrial applications.ResultsWe have engineered the metabolism of B. megaterium to produce heparosan, using a T7 RNA polymerase (T7 RNAP) expression system. This system, which allows tightly regulated and efficient induction of genes of interest, has been co-opted for control of Pasteurella multocida heparosan synthase (PmHS2). Specifically, we show that B. megaterium MS941 cells co-transformed with pT7-RNAP and pPT7_PmHS2 plasmids are capable of producing heparosan upon induction with xylose, providing an alternate, safe source of heparosan. Productivities of ~ 250 mg/L of heparosan in shake flasks and ~ 2.74 g/L in fed-batch cultivation were reached. The polydisperse Pasteurella heparosan synthase products from B. megaterium primarily consisted of a relatively high molecular weight (MW) heparosan (~ 200–300 kD) that may be appropriate for producing certain biomaterials; while the less abundant lower MW heparosan fractions (~ 10–40 kD) can be a suitable starting material for heparin synthesis.ConclusionWe have successfully engineered an asporogenic and non-pathogenic B. megaterium host strain to produce heparosan for various applications, through a combination of genetic manipulation and growth optimization strategies. The heparosan products from B. megaterium display a different range of MW products than traditional E. coli K5 products, diversifying its potential applications and facilitating increased product utility.

High cell density cultivation of a recombinant Escherichia coli strain expressing a 6-O-sulfotransferase for the production of bioengineered heparin.

High Cell Density Cultivation of Recombinant Escherichia coli Strains Expressing 2- O -Sulfotransferase and C5-Epimerase for the Production of Bioengineered Heparin

High-Level Expression and Purification of Recombinant Heparinase Ⅰ in Escherichia Coli

Soluble Expression and Purification of Heparinase I in Escherichia Coli Using a Hexahistidine-Tagged Small Ubiquitin-Like Modifier As a Fusion Partner

Optimization of Bioprocess Conditions Improves Production of a CHO Cell-Derived, Bioengineered Heparin.

Expression and secretion of glycosylated heparin biosynthetic enzymes using Komagataella pastoris

Construction Of Engineered E-Coli System For The Overproduction Of Soluble Heparinase I

Biosynthetic production of anticoagulant heparin polysaccharides through metabolic and sulfotransferases engineering strategies

Using Engineered 6-O-sulfotransferase to Improve the Synthesis of Anticoagulant Heparin

Immobilized Enzymes to Convert N-sulfo, N-acetyl Heparosan to a Critical Intermediate in the Production of Bioengineered Heparin

Construction of recombinant for over-production of soluble heparinase I by fusion to maltose-binding protein

E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor

Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin

Engineering the probiotic bacterium Escherichia coli Nissle 1917 as an efficient cell factory for heparosan biosynthesis

Metabolic engineering of Bacillus megaterium for heparosan biosynthesis using Pasteurella multocida heparosan synthase, PmHS2

Metabolic Engineering of Cyanobacteria for Photoautotrophic Production of Heparosan, a Pharmaceutical Precursor of Heparin

Enhanced Soluble Expression of Recombinant Flavobacterium Heparinum Heparinase I in Escherichia Coli by Fusing It with Various Soluble Partners.

Engineering of a Pichia pastoris Expression System for High-Level Secretion of HSA/GH Fusion Protein

Coordinated optimization of the polymerization and transportation processes to enhance the yield of exopolysaccharide heparosan

Bioengineered Chinese Hamster Ovary Cells with Golgi-Targeted 3-O-sulfotransferase-1 Biosynthesize Heparan Sulfate with an Antithrombin-Binding Site

High-level expression of soluble human epidermal growth factor in Escherichia coli